Raymond Kelleher

Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA.

Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA.

BiVACOR, Inc. develops and manufactures medical device. The firm specializes in rotary blood pumps, biomedical engineering. The company was founded by Daniel Timms in 2008 and is headquartered in Houston, TX.

ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland.

Garuda Therapeutics, Inc. aims to eliminate the need for donor or patient cells for blood stem cell transplants. The company is based in Natick, MA. The company's platform technology generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free. This technology could potentially provide curative therapies for over 120 diseases. Garuda Therapeutics was founded by Dhvanit Shah, Sean Morrison, and David T. Scadden, with Dhvanit Shah serving as CEO since incorporation.

Cormorant Asset Management LP/Private Equity/ (Cormorant Asset Management/Private Equity/) is a venture capital division of Cormorant Asset Management LP founded in 2013 by Bi Hua Chen. The firm is headquartered in Boston, Massachusetts.

GC Therapeutics, Inc. is a company based in Cambridge, MA. GC Therapeutics uses synthetic biology to program stem cells into any cell type with efficiency, speed, and scalability. The company has validated cells for many applications and have developed supercells™ by tailoring cells for specific diseases. The company's goal is to bring this breakthrough approach to patients. The company was founded in 2019 by Parastoo Khoshakhlagh, Alex Ng, Cory Smith, and George McDonald Church, with Parastoo Khoshakhlagh as the CEO since 2019.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.